An iron-based contrast agent with large molecular size, which prevents diffusion into body tissues and will be developed for MR imaging of the liver (taken up by macrophages), tumor microvasculature and microvessel permeability. The blood half live of the particles with 11-20 nm diameter is 3-4 hours.
At this time the development of Clariscan™ is discontinued.

See also NC100150 Injection and Ultrasmall Superparamagnetic Iron Oxide.

MRI coils with a small diameter obtain a higher signal to noise ratio (SNR) than coils with a large diameter. A surface coil with a small diameter can be used to improve the resolution because the area of interest is around the optimal signal depth. The field of view of a (superficial) surface coil is half the diameter of the coil. A disadvantage is a lower sensitive volume of the coil. By combining several coils with small diameters (phased array coil) to record the signal simultaneously and independently, the SNR level improves considerably.

Contrast enhanced GRE sequences provide T2 contrast but have a relatively poor SNR. Repetitive RF pulses with small flip angles together with appropriate gradient profiles lead to the superposition of two resonance signals.
The first signal is due to the free induction decay FID observed after the first and all ensuing RF excitations.
The second is a resonance signal obtained as a result of a spin echo generated by the second and all addicted RF-pulses.
Hence it is absent after the first excitation, it is a result of the free induction decay of the second to last RF-excitation and has a TE, which is almost 2TR. For this echo to occur the gradients have to be completely symmetrical relative to the half time between two RF-pulses, a condition that makes it difficult to integrate this pulse sequence into a multiple slice imaging technique. The second signal not only contains echo contributions from free induction decay, but obviously weakened by T2-decay. Since the echo is generated by a RF-pulse, it is truly T2 rather than T2* weighted. Correspondingly it is also less sensitive to susceptibility changes and field inhomogeneities.
Companies use different acronyms to describe certain techniques.
Different terms (see also acronyms) for these gradient echo pulse sequences:
CE-FAST Contrast Enhanced Fourier Acquired Steady State,
CE-FFE Contrast Enhanced Fast Field Echo,
CE-GRE Contrast Enhanced Gradient-Echo,
DE-FGR Driven Equilibrium FGR,
FADE FASE Acquisition Double Echo,
PSIF Reverse Fast Imaging with Steady State Precession,
SSFP Steady State Free Precession,
T2 FFE Contrast Enhanced Fast Field Echo (T2 weighted).
In this context, 'contrast enhanced' refers to the pulse sequence, it does not mean enhancement with a contrast agent.

The process by which molecules or other particles intermingle and migrate due to their random thermal motion. Microscopic particles are jittering around with translational and rotational motions as a result of their thermal energy, which is half the Boltzmann constant multiplied by the absolute temperature of the system (0.5kT) per degree of freedom (3 directions of translation and 3 directions of rotation for ordinary particles).
MRI provides a sensitive technique for measuring diffusion of some substances. These diffusive processes mean that particles reach areas of low from areas of high concentration, thus leading to equilibration. In body fluids, the distribution of capillaries within tissues is such that transport over macroscopic distances is accomplished by the blood circulation, while over intercapillary distances substances are carried by diffusion. The fluid diffusion constant is itself inversely proportional to the viscosity and the radius of the diffusing particles.

See also Diffusion Tensor Imaging and Diffusion Weighted Imaging.

EP-2104R is a molecularly targeted MRI contrast agent for high resolution blood clot imaging within half an hour of injection. This gadolinium based small peptide has high affinity and specificity for human fibrin.
The thrombus agent is a new class of contrast medium for the diagnostic of, e.g. deep venous thrombosis, carotid artery blood clots, coronary artery blood clots and pulmonary embolism. Fibrin is an excellent target for a molecular imaging contrast agent, since it is present in arterial and venous clots at high concentrations (20-100 μM), and is a target for fibrinolytic therapy.
Due to financial problems, the developer EPIX Pharmaceuticals, Inc. had to shut down all operations. As a consequence, the development of EP-2104R is discontinued.